Abstract:
Objective To investigate the prognostic value of chest computed tomography (CT) characteristics in crizotinib-treated patients with advanced non-small cell lung cancer (NSCLC).
Methods Forty-seven patients with advanced ALK-rearranged NSCLC who received crizotinib treatment from January 2014 to March 2017 were enrolled in this retrospective study. Pre-treatment CT characteristics were evaluated. Patients were followed up after crizotinib treatment, and the best overall response and progression-free survival (PFS) were assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST version 1.1).
Results The median PFS of all patients was 10 months. There was no association between CT characteristics and response. In univariate analysis, large tumor size (P= 0.009), central type (P=0.002), consolidation of surrounding lung tissue (P=0.002), pleural effusion (P=0.001), and lymphangitic carcinomatosis (P=0.019) suggested a poor prognosis. Multivariate Cox regression analysis showed that location (hazard ratio, 3.219; 95% confidence interval: 1.517-6.833; P=0.002) was an independent prognostic predictor.
Conclusions Pre-treatment CT characteristics are useful in predicting the PFS of crizotinib-treated patients with advanced NSCLC harboring ALK rearrangement.